Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VRCA Verrica Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: VRCA
Price (delayed)
$0.5949
Market cap
$55.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
$67.86M
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and
Highlights
The EPS is up by 35% year-on-year and by 23% since the previous quarter
The net income has grown by 18% YoY and by 14% from the previous quarter
Verrica Pharmaceuticals's gross profit has decreased by 28% YoY but it has increased by 7% from the previous quarter
The gross margin has increased by 12% from the previous quarter but it has decreased by 10% YoY
The equity has dropped by 88% since the previous quarter
The quick ratio has plunged by 59% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of VRCA
Market
Valuations
Earnings
Shares outstanding
92.49M
Market cap
$55.02M
Enterprise value
$67.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
7.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.45
Revenue
$7.18M
Gross profit
$5.14M
Operating income
-$55.45M
Net income
-$65.99M
EBIT
-$56.69M
EBITDA
-$55.56M
Free cash flow
-$53.68M
Per share
Balance sheet
Liquidity
EPS
-$1.14
EPS diluted
-$1.14
Free cash flow per share
-$0.57
Book value per share
-$0.2
Revenue per share
$0.08
TBVPS
$0.44
Total assets
$42.18M
Total liabilities
$60.75M
Debt
$42.43M
Equity
-$18.58M
Working capital
$10.08M
Debt to equity
-2.28
Current ratio
1.34
Quick ratio
1.2
Net debt/EBITDA
-0.23
Margins
Efficiency
Dividend
EBITDA margin
-773.9%
Gross margin
71.6%
Net margin
-919.2%
Operating margin
-772.4%
Return on assets
-145.6%
Return on equity
N/A
Return on invested capital
-170.8%
Return on capital employed
-443.5%
Return on sales
-789.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRCA stock price
How has the Verrica Pharmaceuticals stock price performed over time
Intraday
12.01%
1 week
10.21%
1 month
26.84%
1 year
-92.84%
YTD
-15.01%
QTD
34.53%
Financial performance
How have Verrica Pharmaceuticals's revenue and profit performed over time
Revenue
$7.18M
Gross profit
$5.14M
Operating income
-$55.45M
Net income
-$65.99M
Gross margin
71.6%
Net margin
-919.2%
Verrica Pharmaceuticals's gross profit has decreased by 28% YoY but it has increased by 7% from the previous quarter
VRCA's operating income is up by 28% year-on-year and by 16% since the previous quarter
The revenue has declined by 19% year-on-year and by 5% since the previous quarter
The net income has grown by 18% YoY and by 14% from the previous quarter
Price vs fundamentals
How does VRCA's price correlate with its fundamentals
Growth
What is Verrica Pharmaceuticals's growth rate over time
Valuation
What is Verrica Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
7.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.45
The EPS is up by 35% year-on-year and by 23% since the previous quarter
The equity has dropped by 88% since the previous quarter
The stock's price to sales (P/S) is 86% less than its 5-year quarterly average of 58.1 and 26% less than its last 4 quarters average of 10.6
The revenue has declined by 19% year-on-year and by 5% since the previous quarter
Efficiency
How efficient is Verrica Pharmaceuticals business performance
The return on assets has declined by 39% year-on-year but it has grown by 2.3% since the previous quarter
The return on invested capital has increased by 24% year-on-year and by 3.7% since the previous quarter
The ROS is up by 11% since the previous quarter and by 5% year-on-year
Dividends
What is VRCA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRCA.
Financial health
How did Verrica Pharmaceuticals financials performed over time
Verrica Pharmaceuticals's total assets is 31% lower than its total liabilities
The quick ratio has plunged by 59% YoY and by 25% from the previous quarter
Verrica Pharmaceuticals's current ratio has shrunk by 58% YoY and by 24% QoQ
Verrica Pharmaceuticals's debt to equity has plunged by 107% YoY but it has soared by 51% from the previous quarter
The equity has dropped by 88% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.